Under the terms of the agreement, Salus is granted exclusive rights to market and sell Pepaxti in Slovenia, Croatia, Hungary, Slovakia, the Czech Republic, Poland, Bulgaria, Romania, Lithuania, Latvia, and Estonia.

According to company estimates, the CEE region approximately represents a market potential of 150 million SEK for Pepaxti. Through the partnership with Salus, Oncopeptides is addressing the market potential in these countries significantly earlier than anticipated in the company’s original launch plan.

"We are proud to partner with Oncopeptides to bring this important therapy to patients across the CEE region. At Salus, our mission is to bridge the gap between medical innovation and the patients who need it most,” says Žiga Hieng, CEO of Salus. “We look forward to leveraging our deep local expertise to ensure that patients in these key markets gain access to Pepaxti as quickly as possible."

Salus will be responsible for local regulatory processes, market access, and commercialization in the agreed territories, while Oncopeptides retains the overall responsibility for the manufacturing and supply of the drug. Sales revenues generated within the agreed territories shall be shared between Oncopeptides and Salus, with Oncopeptides entitled to the greater portion thereof.

“We are very pleased to enter this partnership with Salus, whose strong regional presence and expertise make them the ideal partner for this market,” says Sofia Heigis, CEO of Oncopeptides. “This agreement enables us to make Pepaxti available to patients in Central and Eastern Europe faster than originally planned. We see significant strategic value in the fact that revenue streams from these markets are now projected to arrive earlier than assumed in our previous launch strategy.”

For more information, please visit www.oncopeptides.com, where a Q&A for investors will also be published.